Irritable bowel syndrome

2019 ◽  
Vol 12 (9) ◽  
pp. 497-500
Author(s):  
Matthew Sutcliffe
Keyword(s):  
Primary Care ◽  
Irritable Bowel Syndrome ◽  
Abdominal Discomfort ◽  
Bowel Habit ◽  
Gastrointestinal Disorders ◽  
Functional Bowel Disorder ◽  
Delay In Diagnosis ◽  
Altered Bowel Habit ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is a functional bowel disorder that commonly presents in primary care and has an array of symptoms including abdominal discomfort and altered bowel habit. There may be an overlap of symptoms with other gastrointestinal disorders, leading to difficulty or delay in diagnosis. The condition can produce a variety of troublesome physical and psychological sequelae causing significant impact on an individual’s quality of life. The aim of this article is to highlight the ways in which IBS can present to the General Practitioner and guide the approach to investigation, diagnosis and management in primary care.

scholarly journals Approach to a Child with Irritable Bowel Syndrome: A Review

2017 ◽  
Vol 2 (1) ◽  
pp. 34-39
Author(s):  
Md Rukunuzzaman ◽  
ASM Bazlul Karim ◽  
Wahiduzzaman Mazumder ◽  
Mohammed Nurullah ◽  
Faika Hussain ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Functional Gastrointestinal Disorders ◽  
Physiological Mechanism ◽  
Bowel Habit ◽  
Gastrointestinal Disorders ◽  
Rome Iii Criteria ◽  
Functional Bowel Disorder ◽  
Rome Iii ◽  
Irritable Bowel ◽  
Bowel Disorder

Irritable bowel syndrome (IBS) is one of the most common and best studied disorders among the group of functional gastrointestinal disorders. It is a functional bowel disorder in which abdominal pain or discomfort is associated with defecation or a change in bowel habit. Visceral hypersensitivity and increased GIT motility are the main patho-physiological mechanism for developing IBS. IBS present with diarrhoea or constipation or both. Investigations are least needed for diagnosis of IBS rather done to exclude differential diagnosis. Diagnosis of IBS is done on the basis of Rome-III criteria. Proper counseling, dietary management, antispasmotic and antidepressant are the mainstay of treatment. Journal of National Institute of Neurosciences Bangladesh, 2016;2(1): 34-39

scholarly journals Impact of Opioid Consumption in Patients With Functional Gastrointestinal Disorders

2020 ◽  
Vol 11 ◽  
Author(s):  
Chloé Melchior ◽  
Charlotte Desprez ◽  
Fabien Wuestenberghs ◽  
Anne-Marie Leroi ◽  
Antoine Lemaire ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Functional Dyspepsia ◽  
Functional Gastrointestinal Disorders ◽  
Opioid Consumption ◽  
University Hospital ◽  
Gastrointestinal Disorders ◽  
Gi Symptoms ◽  
Irritable Bowel

Objective: We aimed to determine the burden of opioid consumption in a cohort of patients with functional gastrointestinal disorders.Methods: All patients diagnosed with functional gastrointestinal disorders and referred to our university hospital were evaluated from 2013 to the beginning of 2019. Irritable bowel syndrome and functional dyspepsia diagnoses were determined according to Rome criteria and severity according to irritable bowel syndrome severity scoring system. Vomiting was quantified using a 5-point Likert scale, and constipation severity was measured using the Knowles-Eccersley-Scott-Symptom questionnaires. Quality of life was quantified by the GastroIntestinal Quality of Life Index. Patients were categorized as being treated on a chronic basis with either tramadol, step II opioids, step III opioids or as being opioid-free.Results: 2933 consecutive patients were included. In our cohort, 12.5% had only irritable bowel syndrome, 39.3% had only functional dyspepsia, 24.9% had a combination of both, and 23.4% had other functional gastrointestinal disorders. Among them, the consumption of tramadol, step II (tramadol excluded) and step III opioids was 1.8, 1.3 and 0.3 % respectively in 2013 and 4.3, 3.4 and 1.9% in 2018 (p < 0.03). Opioid consumption was associated with increased vomiting (p = 0.0168), constipation (p < 0.0001), symptom severity (p < 0.001), more altered quality of life (p < 0.0001) and higher depression score (p = 0.0045).Conclusion: In functional gastrointestinal disorders, opioid consumption has increased in the last years and is associated with more GI symptoms (vomiting, constipation and GI severity), higher depression and more altered quality of life.

scholarly journals Irritable bowel syndrome: towards an integrated approach

1999 ◽  
Vol 4 (1) ◽  
pp. 45-46 ◽  
Author(s):  
Anita D Stuart ◽  
H Gertie Pretorius ◽  
Lynette Van der Merwe
Keyword(s):  
North Carolina ◽  
Irritable Bowel Syndrome ◽  
Functional Gastrointestinal Disorders ◽  
Gastrointestinal Symptoms ◽  
Integrated Approach ◽  
Gastrointestinal Disorders ◽  
University Of North Carolina ◽  
Irritable Bowel ◽  
The Impact

Functional Gastrointestinal Disorders are defined as chronic or recurrent gastrointestinal symptoms characterized by abdominal pain, constipation and/or diarrhoea (Tally, 1994; University of North Carolina, 1998). These disorders are of concern because of their high incidence, associated morbidity, expense and the impact of these disorders on people's quality of life. Drossman (1993, in University of North Carolina (UNC), 1998) found that of 5 400 U.S. households, 69% of people met the criteria for at least one of the functional gastrointestinal disorders which represents a 59% increase in the incidence of functional gastrointestinal disorders since 1983 (Drossman, in UNC, 1998; Drossman, 1983). In particular, Irritable Bowel Syndrome (IBS) sufferers account for 2,4 - 3,5 million visits to doctors annually. Furthermore, IBS sufferers spend $40 million annually on treatment for their condition. They also tend to have 3 to 4 times more disability days than other workers, which illustrates the debilitating effect of this disorder (Drossman, in UNC, 1998). It is therefore necessary that the etiology of IBS be researched, as well as the course and management of this debilitating disease. The studies presented in this series aimed to improve the understanding of the multiple agents that influence the development and course of IBS.

scholarly journals The role of abuse in the development of irritable bowel syndrome: a comparative study

2003 ◽  
Vol 8 (4) ◽  
pp. 88-98
Author(s):  
G Eileen Rossouw ◽  
Anita D Stuart ◽  
H Gertie Pretorius
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Comparative Study ◽  
Full Text ◽  
Bowel Habit ◽  
Functional Bowel Disorder ◽  
Irritable Bowel ◽  
Bowel Disorder

Irritable Bowel Syndrome (IBS) is defined as a chronic relapsing functional bowel disorder of unknown causes which is characterised by attacks of abdominal pain and change of bowel habit resulting in diarrhoea or constipation or both. Opsomming Prikkelbare Dermsindroom (PDS) word gedefinieer as ’n chroniese, herhalende, funksionele ingewandsversteuring wat gekenmerk word deur aanvalle van buikpyn en ‘n verandering in ingewandsgewoontes, wat diarree of hardlywigheid, of beide, tot gevolg het. *Please note: This is a reduced version of the abstract. Please refer to PDF for full text.

Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study

2018 ◽  
Vol 9 (4) ◽  
pp. 563-572 ◽  
Author(s):  
M. Ratna Sudha ◽  
N. Jayanthi ◽  
M. Aasin ◽  
R.D. Dhanashri ◽  
T. Anirudh
Keyword(s):  
Irritable Bowel Syndrome ◽  
Placebo Group ◽  
Pain Intensity ◽  
Bacillus Coagulans ◽  
Treated Group ◽  
Abdominal Discomfort ◽  
Bowel Habit ◽  
Age Group ◽  
Double Blind ◽  
Irritable Bowel

The efficacy of the probiotic strain, Bacillus coagulans Unique IS2 in the treatment of Irritable Bowel Syndrome (IBS) was evaluated in children. A total of 141 children of either sex in the age group 4-12 years, diagnosed with IBS according to the Rome III criteria, participated in the double-blind randomised controlled trial. Children received either B. coagulans Unique IS2 chewable tablets or placebo once daily for eight weeks followed by a two week follow-up period. Reduction in pain intensity as well as other symptoms associated with Irritable Bowel Syndrome like abdominal discomfort, bloating, distension, sense of incomplete evacuation, straining at stool, urgency of bowel movement, passage of gas and mucus, and bowel habit satisfaction were assessed. B. coagulans Unique IS2 treated group showed a greater reduction in pain scores as evaluated by a weekly pain intensity scale. There was a significant reduction (P<0.0001) in pain intensity in the probiotic treated group (7.6±0.98) as compared to the placebo group (4.2±1.41) by the end of the treatment period (8 weeks). There was also a significant improvement in stool consistency as well as reduction in abdominal discomfort, bloating, staining, urgency, incomplete evacuation and passage of gas. Bowel habit satisfaction and global assessment of relief was also observed in the B. coagulans Unique IS2 treated group as compared to the placebo group. This study demonstrates the efficacy of B. coagulans Unique IS2 in reducing the symptoms of Irritable Bowel Syndrome in children in the age group of 4-12 years.

scholarly journals Treating irritable bowel syndrome with probiotics: the evidence

2010 ◽  
Vol 69 (2) ◽  
pp. 187-194 ◽  
Author(s):  
G. C. Parkes ◽  
J. D. Sanderson ◽  
K. Whelan
Keyword(s):  
Irritable Bowel Syndrome ◽  
Bacterial Overgrowth ◽  
Abdominal Distension ◽  
Small Intestinal Bacterial Overgrowth ◽  
Bowel Habit ◽  
Altered Bowel Habit ◽  
Small Intestinal ◽  
Irritable Bowel ◽  
Developed World ◽  
Post Infectious

Irritable bowel syndrome (IBS) is a disorder of chronic abdominal pain, altered bowel habit and abdominal distension. It is the commonest cause of referral to gastroenterologists in the developed world and yet current therapeutic strategies are often unsatisfactory. There is now increasing evidence linking alterations in the gastrointestinal (GI) microbiota and IBS. Changes in faecal and mucosa-associated microbiota, post-infectious IBS, a link with small intestinal bacterial overgrowth and an up-regulation of the GI mucosal immune system all suggest a role for the GI microbiota in the pathogenesis of IBS. Given this evidence, therapeutic alteration of the GI microbiota by probiotic bacteria could be beneficial. The present paper establishes an aetiological framework for the use of probiotics in IBS and comprehensively reviews randomised placebo-controlled trials of probiotics in IBS using multiple electronic databases. It highlights safety concerns over the use of probiotics and attempts to establish guidelines for their use in IBS in both primary and secondary care.

Sign in / Sign up

Export Citation Format

Share Document